Opinion
Zacks Investment Research on MSN2dOpinion
Top Stock Reports for Tesla, Home Depot & Boston Scientific
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), The Home Depot, ...
BioSpace3d
Opthea, UNITY Fail to Unseat Regeneron’s Eylea in Vision Disorders
The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...
Clinical Trials Arena on MSN4d
Opthia could owe $1bn to investors amid sozinibercept trial failure
The Australian biotech could potentially be on the hook for more than $1bn after its Wet AMD therapy failed to show impact ...
Endpoints News4d
Two biotechs fail to beat or match Re­gen­eron's Eylea in key tri­als
Opthea's sozinibercept and Unity's UBX1325 fail to match Regeneron's Eylea in separate eye disease trials; Opthea faces ...
Fierce Biotech4d
Unity's eye treatment fails to match Eylea, though analysts still see a path forward
Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...
Fierce Biotech4d
Opthea's eye disease drug defeated by Eylea in phase 3, leaving biotech to mull future
Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...